NYSE · OGN
Organon & Co.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OGN: Nov 9, 2026
Organon & Co. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.95. The reported EPS for the same quarter last year was $0.93.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.95 | $0.95 | $0.95 | 1 |
| Dec 2026 | $0.80 | $0.80 | $0.80 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat- Zacks · Oct 30, 8:30 AM EDTOrganon (OGN) Q3 Earnings and Revenues Top EstimatesOrganon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 26, 8:00 AM EDTOrganon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItOrganon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Zacks · Oct 14, 8:00 AM EDTInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowRecently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
- RTTNews · Oct 8, 5:59 AM EDTBiotech Stocks At 52-Week Highs – ABBV On FDA Designations, HSTM, OGN(RTTNews) – The following biotech stocks reached a 52-week high on October 6, 2026, driven by catalysts such as achieving new regulatory milestones.
- Zacks · Oct 2, 8:00 AM EDTHere is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockOrganon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- RTTNews · Sep 28, 9:23 AM EDTOrganon Canada Gets Approval For NDUVRA 1% Non-Steroid Cream For Atopic Dermatitis(RTTNews) – Organon Canada, a subsidiary and regional affiliate of Organon & Co. (OGN) announced on Monday the approval of NDUVRA or Tapinarof cream, 1%, a new steroid-free topical treatment for moderate to severe atopic dermatitis in adult and pediatric patients of two years and
- Zacks · Sep 21, 9:00 AM EDTIs Trending Stock Organon & Co. (OGN) a Buy Now?Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- RTTNews · Sep 14, 8:37 AM EDTOrganon's MIUDELLA SNDA Accepted For FDA Review To Extend Use To 6 Years(RTTNews) – Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MIUDELLA, a hormone-free copper intrauterine device (IUD), seeking to extend its approved duration of use from three to six
- Zacks · Sep 8, 9:00 AM EDTOrganon & Co. (OGN) is Attracting Investor Attention: Here is What You Should KnowZacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Zacks · Jul 31, 11:00 AM EDTCompared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key MetricsAlthough the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks · Jul 31, 9:45 AM EDTOrganon (OGN) Lags Q2 Earnings EstimatesOrganon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Jul 23, 11:07 AM EDTOrganon & Co. Shareholders Clear Sun Pharma Merger DealMerck, the Dow's hottest stock, gets set to report Q4 financialsShareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting result
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Organon & Co. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.